Seres Therapeutics' IBD Candidate SER-603 Shows Positive Preclinical Data, Advances Towards IND
Summary
Seres Therapeutics presented positive preclinical data for SER-603, a next-generation live biotherapeutic candidate for Inflammatory Bowel Disease (IBD), at Digestive Disease Week (DDW) 2026. The data highlighted SER-603's rational design targeting microbial functions linked to mucosal healing and GI inflammation, with the presentation earning a 'Poster of Distinction'. This update is significant as the company is advancing SER-603 through IND-enabling activities and engaging potential collaborators for clinical development. This positive pipeline news provides a much-needed boost, especially after the company issued a going concern warning and paused its lead clinical program (SER-155 Phase 2) due to funding issues, as noted in its last 10-K. Traders will be watching for further progress on IND-enabling activities and any potential collaboration agreements that could provide funding and advance SER-603 into human trials.
At the time of this announcement, MCRB was trading at $7.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.3M. The 52-week trading range was $6.53 to $29.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.